These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9689575)

  • 1. Clinical implications of HIV dynamics and drug resistance in macrophages.
    Aquaro S; Caliò R; Balestra E; Bagnarelli P; Cenci A; Bertoli A; Tavazzi B; Di Pierro D; Francesconi M; Abdelahad D; Perno CF
    J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):23-7. PubMed ID: 9689575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between HIV-inhibiting drug activity in human macrophages and clinical outcome].
    Aquaro S; Balestra E; Panti S; Cenci A; Serra F; Francesconi M; Abdelahad D; Caliò R; Perno CF
    Clin Ter; 1998; 149(921):37-41. PubMed ID: 9621487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies towards HIV-1 infection in macrophages.
    Perno CF; Svicher V; Schols D; Pollicita M; Balzarini J; Aquaro S
    Antiviral Res; 2006 Sep; 71(2-3):293-300. PubMed ID: 16806514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.
    Aquaro S; Svicher V; Schols D; Pollicita M; Antinori A; Balzarini J; Perno CF
    J Leukoc Biol; 2006 Nov; 80(5):1103-10. PubMed ID: 16931601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV infection in macrophage: role of long-lived cells and related therapeutical strategies.
    Aquaro S; Balestra E; Cenci A; Francesconi M; Caliò R; Perno CF
    J Biol Regul Homeost Agents; 1997; 11(1-2):69-73. PubMed ID: 9418167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular factors for resistance against antiretroviral agents.
    Fridland A; Connelly MC; Robbins BL
    Antivir Ther; 2000 Sep; 5(3):181-5. PubMed ID: 11075937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy.
    Davis C; Heredia A; Le N; Dominique JK; Redfield RR
    J Hum Virol; 2001; 4(3):113-22. PubMed ID: 11572234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
    Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
    J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication.
    Crowe SM; Sonza S
    J Leukoc Biol; 2000 Sep; 68(3):345-50. PubMed ID: 10985250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
    J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection.
    Gross E; Amella CA; Pompucci L; Franchin G; Sherry B; Schmidtmayerova H
    J Leukoc Biol; 2003 Nov; 74(5):781-90. PubMed ID: 12960233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophages--promise and peril.
    TreatmentUpdate; 1998 Dec; 10(10):4-5. PubMed ID: 11366018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophages: a crucial reservoir for human immunodeficiency virus in the body.
    Balestra E; Perno CF; Aquaro S; Panti S; Bertoli A; Piacentini M; Forbici F; D'Arrigo R; Calió R; Garaci E
    J Biol Regul Homeost Agents; 2001; 15(3):272-6. PubMed ID: 11693436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
    Désormeaux A; Bergeron MG
    Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.